Cytological evaluation of specimens obtained by fine-needle aspiration (FNA) is a useful method to diagnose malignancies in patients with accessible lesions. To improve the accuracy of FNA-based diagnosis, previous investigations have attempted to combine FNA biopsies and molecular techniques with limited success. In this report, we describe a large study designed to determine the accuracy of diagnostic and prognostic gene expression ratio tests in malignant pleural mesothelioma (MPM) using RNA from ex-vivo with median survival between 9 and 12 months. The correct diagnosis of MPM is sometimes challenging and usually requires solid tissue biopsies rather than fine needle aspiration biopsies (FNA). We postulated that the accuracy of FNA-based diagnosis might be improved by the addition of molecular tests using a gene expression ratio-based algorithm and that prognostic tests could be similarly performed.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive pleural malignancy, usually associated with previous asbestos exposure. Although MPM is a relatively rare disease with an annual incidence in the US of 2,000 to 3,000 cases, a continuing rise in its incidence has been reported world-wide, presumably due to the continuing unabated use of asbestos in most countries as well as to the long lag period between exposure and presentation (1, 2) . Making the correct histological diagnosis of MPM is occasionally challenging and requires structural evaluation and complex immunohistochemical panels (3) . These difficulties are a particular problem for fine needle aspiration (FNA) biopsies, necessitating open surgical biopsies in the majority of patients prior to definitive diagnosis (4) . The median survival for most MPM patients is between 9 and 12 months reflecting the fact that there are few effective therapies (5, 6) . Some patients are eligible for a multimodal approach based on a combination of surgery, chemo-and radiation therapy. This method has been reported to improve survival in surgically resected patients who have epithelial histology and are without lymph node involvement or distant metastases (7) . Unfortunately, current staging systems to predict outcome also require major surgery.
To address limitations in diagnosis and prognosis in MPM, we have used a gene expression approach to develop specific molecular tests. We have previously generated ratio-based tests to discriminate MPM from lung adenocarcinoma (8) , and to predict the outcome of MPM patients (9) (10) (11) . Both tests were validated in several independent retrospective tissue biopsy sample sets as well as in an additional independent prospective cohort (9) (10) (11) (8, 9) . For the diagnostic test, the relative expression levels of the 6 genes (CALB2, claudin-7, AnnexinA8, EPCAM, CD200, NKX2-1) were determined by RT-PCR in order to calculate a combined score (i.e., geometric mean) of three individual gene pair expression ratios (CALB2/claudin-7, AnnexinA8/EPCAM, CD200/NKX2-1). FNA samples were assigned to the diagnosis of mesothelioma when the combined score was >1 and lung adenocarcinoma when the combined score was <1, exactly as previously described (8 For the prognostic test, the relative expression levels of 4 genes (COBLL1, ARHGDIA1, TM4SF1, and PKM2) were established by RT-PCR in the MPM samples, and the geometric mean of three individual gene pair expression ratios (COBLL1/ARHGDIA1, TM4SF1/PKM2, TM4SF1/ARHGDIA1) was calculated for each sample. The MPM FNA biopsies were assigned to either a good-(combined score >1) or poor-outcome (combined score <1) group exactly as previously described (10, 11).
Data and Statistical Analysis
The final diagnosis or prognosis for a patient using the gene ratio expression test was determined by a "majority rule" pooling across all the analyzed FNA samples. In the event of an equal number with differential assignments, the final diagnosis or prognosis for a patient was determined based on the FNA sample with the most extreme geometric mean. The decision to use the value furthest away from the threshold of one is motivated by our previous observations that numerical values close to one were within the margin of assay error in terms of technical performance (9).
The 95% confidence interval (95% CI) for rates of sensitivity, specificity and concordance were based on the exact binomial distribution. McNemar's test was used to assess the concordance of test results between different starting amounts of total RNA among the FNA samples obtained from the same patient. To determine whether the results of the gene-ratio expression test was assigning a random diagnosis, a one-sample exact binomial procedure was used to test a null hypothesis with the proportion of 0.5. (Tables 1 and 2 ). All patients underwent extirpative surgery. Of these, 42 patients (67%) underwent extrapleural pneumonectomy, whereas the remaining patients underwent a radical pleurectomy. Only one patient had received neoadjuvant chemotherapy. However, most of the patients (73%) were also treated with intraoperative installation of heated cisplatin into the pleural and peritoneal cavities after tumor resection.
In addition, we analyzed 250 ex-vivo FNA samples from 92 lung cancer patients with at least 1 μg RNA available. Although the diagnostic test was originally designed to distinguish MPM from primary lung adenocarcinoma, we also included in the analysis FNA biopsies from patients with adenocarcinoma metastatic to the lung from non-lung primaries. The histological classifications of all tumors are listed in Table 1 . Notably, all 6 patients (100%) with metastatic adenocarcinoma were diagnosed correctly, despite the different primary tumor sites. No significant differences in diagnosis were found whether the starting RNA content for analysis was 2 μg or 500 ng. In the primary lung adenocarcinoma group concordance was 88% (95% CI: 64-99%) based on the 17 patients with multiple FNA samples with different starting amounts of total RNA (Table   3) .
We next examined the results of our previously validated prognostic test in the MPM FNA specimens. First, we compared the outcomes of the test based on starting amounts of RNA. Among the 63 MPM patients, 37 were analyzed using FNA samples with both 2 μg and 500 ng of total RNA. The concordance between assays for the prognostic test using 2 μg or 500 ng of total RNA was 95% (95% CI: 82-99%) showing that the results were independent of the starting amounts of total RNA used to perform the test. We then examined risk classification among the patients. The prognostic test assigned 50 of 63 patients (79%) to good prognosis and 13 of 63 patients (21%) to poor prognosis. Because this prospective cohort was not sufficiently distributed to examine Table 4 .
Discussion
FNA biopsy, whether image-guided or performed by direct palpation, is a clinically common and useful diagnostic method in patients with presumed neoplasms. It is less invasive than an open biopsy or a core needle biopsy and is, therefore, associated with less discomfort and a lower risk of bleeding, pneumothorax, or viscous perforation (17) . However, the accuracy, specificity and sensitivity of the cytological interpretation of FNA biopsies may be limited in a variety of circumstances such as target size, tumor type, accessibility etc. One major limitation is the need for intact recognizable tumor cells and architecture for definitive histological typing and diagnosis (12) . Even when tumor is detected, the histological subtype and features associated with prognosis may not be ascertainable. We hypothesized that the addition of molecular tests such as gene expression analysis to the cytological analysis for FNA biopsies would potentially enhance the sensitivity and specificity of this method for cancer diagnosis as well as for application of prognostic and pharmacogenomic tests.
We previously reported that the combination of a small number of carefully chosen and validated gene expression ratios can be used to develop diagnostic and prognostic tests for cancer. We proposed specific tests for diagnosis of MPM, lung 
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Copyright © 2010 American Association for Cancer Research applied to a large number of ex-vivo FNA biopsies from MPM and adenocarcinoma is 100% sensitive and 90% specific. We also examined the performance of a prognostic test that had previously been prospectively validated for MPM in solid tumor biopsies (9) . We demonstrated that the test was feasible using 500 ng of starting total RNA and that it was concordant in the majority of the cases with the same test applied to matched solid tumor specimens. While the FNA-based classification was 74% concordant with surgical specimens overall, the specificity for good risk patients was particularly high at 97%. MPM is a highly lethal tumor for which few therapies are effective (5, 6), therefore, it is important to identify upfront those patients who might benefit from aggressive surgery. Thus, the finding that the FNA approach is quite effective in identifying the good risk patients is associated with high clinical utility.
There are several limitations of this study. One is that the biopsies were done in ex-vivo specimens and it is possible that the RNA yield or tumor accessibility of in-vivo FNA speciemens will be less adequate. However, the success of the ex-vivo biopsies suggests that with careful modulation of the image guidance technique and the biopsy procedure this approach can be translated into an image-guided in-vivo FNA biopsy procedure. This hypothesis is currently being addressed in a clinical trial at our institution. Another limitation is that while correctly identifying the good prognosis patients, the prognostic test was insufficiently specific for the poor prognosis patients.
This test property can be potentially overcome by either combining the molecular test information with additional radiological and clinical tests to design risk stratification algorithms and/or by performing new discovery experiments to define better molecular tests specific to FNA biopsies. Several reports have described the application of direct or ultrasound-guided FNA combined with molecular testing in breast (22) and thyroid cancer (23) . A pilot study has been conducted using FNAs from primary breast cancers to identify quality control criteria for individual microarray and to assess whether gene expression profiles obtained from the FNAs were representative of the tumors (24) . Although the results displayed that only 15% of the FNAs provided enough mRNA for the expression array analysis, the study established some guidelines to combine FNA with cDNA microarray technology.
In addition, the amplification of the extracted RNA was successfully utilized in another FNA study to examine pathways of chemoresistance in breast cancer but not for diagnosis or prognosis (25) .
One of the most commonly used FNA-based cytological tests is for the diagnosis of thyroid cancer within thyroid nodules. Unfortunately, up to 30% of thyroid FNA biopsies are indeterminate and these patients often require a diagnostic thyroidectomy (26) . A recent study has been performed to determine the diagnostic accuracy of a 3-gene assay in thyroid tumor tissue and in clinical FNA biopsy samples for distinguishing benign from malignant thyroid neoplasms (27) . Although 2 of the 3 proposed gene markers were significantly differentially expressed in malignant thyroid tissue and clinical FNA biopsies, the characteristic curve analysis for these 3 genes, individually or in combination, did not display sufficient accuracy to distinguish benign from malignant thyroid neoplasms in either FNA biopsy or tissue samples. Another effort to discriminate between benign follicular thyroid adenoma and malignant follicular thyroid carcinoma by using FNA biopsy analysis at the transcript level has been reported by Cerutti et al (28) .
Although the main focus was on the immunohistochemistry of four proteins, the In the present study, we demonstrate for the first time that sufficient RNA can be extracted from most FNA biopsies to allow for gene-ratio based analysis using specific diagnostic and prognostic tests in MPM and lung cancer. We envision this method as an adjunct to increase the accuracy and spectrum of tests that may be done via this approach for thoracic cancer specifically and all cancers in general.
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